- Home
- ABVX vs IBRX Comparison
ABVX vs IBRX Comparison
Compare ABVX & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABVX | IBRX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | France | United States |
| Employees | 67 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.4B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ABVX | IBRX |
|---|---|---|
| Price | $119.20 | $7.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $131.31 | $12.57 |
| AVG Volume (30 Days) | 882.8K | ★ 21.8M |
| Earning Date | 03-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $70.74 | $88.59 |
| Revenue Next Year | $3,694.18 | $131.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $5.20 | $1.83 |
| 52 Week High | $148.83 | $12.43 |
Technical Indicators
Market Signals| Indicator | ABVX | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.43 | 44.98 |
| Support Level | $105.48 | $6.54 |
| Resistance Level | $130.20 | $8.28 |
| Average True Range (ATR) | 5.76 | 0.85 |
| MACD | 0.89 | -0.16 |
| Stochastic Oscillator | 70.50 | 16.67 |
Price Performance
Historical ComparisonAbout ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.